hydroxychloroquine has been researched along with Liver Dysfunction in 12 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine and phlebotomy were compared in the treatment of porphyria cutanea tarda (PCT)." | 9.05 | Hydroxychloroquine versus phlebotomy in the treatment of porphyria cutanea tarda. ( Bessone, E; Cainelli, T; Cantoni, L; Di Padova, C; Gori, G; Marchesi, L; Podenzani, SA; Rovagnati, P, 1983) |
| "A review of the literature on the longterm use of methotrexate in patients with rheumatoid arthritis (RA) showed that many questions on protocol remain unanswered." | 8.77 | Longterm methotrexate therapy in rheumatoid arthritis: a review. ( Kremer, JM, 1985) |
| "Six patients with skin changes and urinary porphyrin excretion patterns characteristic for porphyria cutanea tarda were treated with hydroxychloroquine sulfate therapy." | 7.66 | Hydroxychloroquine treatment of porphyria cutanea tarda. ( Levitt, L; Malkinson, FD, 1980) |
| "Hydroxychloroquine and phlebotomy were compared in the treatment of porphyria cutanea tarda (PCT)." | 5.05 | Hydroxychloroquine versus phlebotomy in the treatment of porphyria cutanea tarda. ( Bessone, E; Cainelli, T; Cantoni, L; Di Padova, C; Gori, G; Marchesi, L; Podenzani, SA; Rovagnati, P, 1983) |
| "A review of the literature on the longterm use of methotrexate in patients with rheumatoid arthritis (RA) showed that many questions on protocol remain unanswered." | 4.77 | Longterm methotrexate therapy in rheumatoid arthritis: a review. ( Kremer, JM, 1985) |
| "Six patients with skin changes and urinary porphyrin excretion patterns characteristic for porphyria cutanea tarda were treated with hydroxychloroquine sulfate therapy." | 3.66 | Hydroxychloroquine treatment of porphyria cutanea tarda. ( Levitt, L; Malkinson, FD, 1980) |
| " Recommendations were made based on available data, consideration of pharmacokinetic properties (including variability), the dosing and anticipated treatment duration of each regimen in COVID-19 and known toxicities." | 2.72 | Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. ( Back, D; Boyle, A; Burger, D; Davidson, K; El-Sherif, O; Gibbons, S; Khoo, S; Marra, F; Marzolini, C; Siccardi, M; Smolders, EJ; Sommerville, AJ, 2021) |
| "Physiologically based pharmacokinetic (PBPK) models were used to study the change in the pharmacokinetics (PK) of drugs repurposed for COVID-19 in geriatric patients, different race groups, organ impairment and drug-drug interactions (DDIs) risks." | 1.91 | Pharmacokinetics under the COVID-19 storm. ( El-Khateeb, E; Giovino, N; Jamei, M; Jo, H; Lythgoe, E; Pilla Reddy, V; Rastomi-Hodjegan, A; Sharma, S; Tang, W, 2023) |
| "A treatment with lopinavir/ritonavir and hydroxychloroquine twice daily was started." | 1.56 | Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection. ( Bernasconi, E; Bertoli, R; Cerny, A; Ceschi, A; De Gottardi, A; Fratila, C; Gianella, P; Magenta, L; Majno-Hurst, P; Vanini, G, 2020) |
| "Hepatic cysts arise from cholangiocytes exhibiting a hyperproliferative phenotype." | 1.48 | Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target. ( Ding, JF; Huang, BQ; LaRusso, NF; Loarca, L; Lorenzo Pisarello, MJ; Masyuk, AI; Masyuk, TV, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (50.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| De Gottardi, A | 1 |
| Fratila, C | 1 |
| Bertoli, R | 1 |
| Cerny, A | 1 |
| Magenta, L | 1 |
| Gianella, P | 1 |
| Majno-Hurst, P | 1 |
| Ceschi, A | 1 |
| Vanini, G | 1 |
| Bernasconi, E | 1 |
| Pilla Reddy, V | 1 |
| El-Khateeb, E | 1 |
| Jo, H | 1 |
| Giovino, N | 1 |
| Lythgoe, E | 1 |
| Sharma, S | 1 |
| Tang, W | 1 |
| Jamei, M | 1 |
| Rastomi-Hodjegan, A | 1 |
| Marra, F | 1 |
| Smolders, EJ | 1 |
| El-Sherif, O | 1 |
| Boyle, A | 1 |
| Davidson, K | 1 |
| Sommerville, AJ | 1 |
| Marzolini, C | 1 |
| Siccardi, M | 1 |
| Burger, D | 1 |
| Gibbons, S | 1 |
| Khoo, S | 1 |
| Back, D | 1 |
| Masyuk, AI | 1 |
| Masyuk, TV | 1 |
| Lorenzo Pisarello, MJ | 1 |
| Ding, JF | 1 |
| Loarca, L | 1 |
| Huang, BQ | 1 |
| LaRusso, NF | 1 |
| Khayat, R | 1 |
| Dupuy, A | 1 |
| Pansé, I | 1 |
| Bagot, M | 1 |
| Cordoliani, F | 1 |
| QUEEN, HO | 1 |
| Cainelli, T | 1 |
| Di Padova, C | 1 |
| Marchesi, L | 1 |
| Gori, G | 1 |
| Rovagnati, P | 1 |
| Podenzani, SA | 1 |
| Bessone, E | 1 |
| Cantoni, L | 1 |
| Malkinson, FD | 1 |
| Levitt, L | 1 |
| Joundy, N | 1 |
| Carpentier, S | 1 |
| Leclech, C | 1 |
| Aubé, C | 1 |
| Rousselet, MC | 1 |
| Barré, P | 1 |
| Oberti, F | 1 |
| Calès, P | 1 |
| Bundino, S | 1 |
| Topi, GC | 1 |
| Zina, AM | 1 |
| D'Allessandro Gandolfo, L | 1 |
| Malina, L | 1 |
| Kremer, JM | 1 |
2 reviews available for hydroxychloroquine and Liver Dysfunction
| Article | Year |
|---|---|
Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Dru | 2021 |
Longterm methotrexate therapy in rheumatoid arthritis: a review.
Topics: Arthritis, Rheumatoid; Biopsy; Chemical and Drug Induced Liver Injury; Drug Resistance; Gold; Humans | 1985 |
1 trial available for hydroxychloroquine and Liver Dysfunction
| Article | Year |
|---|---|
Hydroxychloroquine versus phlebotomy in the treatment of porphyria cutanea tarda.
Topics: Adult; Aged; Bloodletting; Humans; Hydroxychloroquine; Liver Diseases; Male; Middle Aged; Porphyrias | 1983 |
9 other studies available for hydroxychloroquine and Liver Dysfunction
| Article | Year |
|---|---|
Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection.
Topics: Antiviral Agents; Comorbidity; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Immuno | 2020 |
Pharmacokinetics under the COVID-19 storm.
Topics: Aged; Computer Simulation; COVID-19; Drug Interactions; Humans; Hydroxychloroquine; Liver Diseases; | 2023 |
Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target.
Topics: Animals; Autophagy; Bile Ducts; Blotting, Western; Cell Proliferation; Cells, Cultured; Cluster Anal | 2018 |
[Sclerodermatous changes in porphyria cutanea tarda: six cases].
Topics: Adrenal Cortex Hormones; Aged; Alcoholism; Alopecia; Diagnosis, Differential; Female; Humans; Hydrox | 2013 |
Hepatic amebiasis treated with plaquenil: case report.
Topics: Amebiasis; Chloroquine; Hydroxychloroquine; Liver Abscess, Amebic; Liver Diseases; North Carolina | 1960 |
Hydroxychloroquine treatment of porphyria cutanea tarda.
Topics: Adult; Coproporphyrins; Female; Humans; Hydroxychloroquine; Iron; Liver Diseases; Male; Middle Aged; | 1980 |
[Favourable course of a pseudotumoral form of hepatic and splenic sarcoidosis under treatment with hydroxychloroquine and colchicine].
Topics: Antimalarials; Colchicine; Drug Therapy, Combination; Female; Gout Suppressants; Humans; Hydroxychlo | 1995 |
Hepatoerythropoietic porphyria.
Topics: Child; Erythropoiesis; Humans; Hydroxychloroquine; Liver Diseases; Male; Porphyrias | 1987 |
Treatment of chronic hepatic porphyria (PCT).
Topics: Bloodletting; Chloroquine; Humans; Hydroxychloroquine; Liver Diseases; Porphyrias | 1986 |